Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Trial Profile

Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Pidilizumab (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2015 Status changed from active, no longer recruiting to discontinued as per M.D. Anderson Cancer Center.
    • 31 Mar 2014 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 25 Mar 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top